Rapid Tuberculosis Biosensor Delivers Results in 60 Minutes

A faster test for one of the world’s deadliest infectious diseases

Researchers at the Technical University of Valencia’s IDM are developing a biosensor designed to detect active tuberculosis in about 60 minutes, a substantial reduction from conventional microbiological culture methods that can take weeks. The work focuses on identifying a protein secreted by Mycobacterium tuberculosis, the bacterium that causes the disease.

The timing matters. Tuberculosis remains a major global health threat, and the source article notes that the World Health Organization’s 2024 global report again identified it as the leading cause of death from a single infectious agent. In that context, a diagnostic tool that is both rapid and clinically targeted could help shorten the time between suspicion, confirmation and treatment decisions.

How the sensor works

The system is built around a nanoporous material containing a fluorescent molecule. The material is coated with an antibody specific to MPT64, a protein associated with active tuberculosis infection. When that protein is present, the antibody shifts and releases the fluorescent compound, producing a detectable light signal.

That design gives the device a distinctive clinical angle. According to the researchers, other molecular techniques such as PCR can detect fragments of bacterial DNA without clearly distinguishing between active, past or latent infection. This sensor instead targets a protein secreted during active disease, which could make the result more useful in real-world care settings where knowing whether a patient has active tuberculosis is crucial.

Why active-disease detection matters

Tuberculosis diagnosis has long involved tradeoffs between speed, sensitivity, cost and specificity. Culture remains important but slow. Molecular tests are faster but may not always answer the exact clinical question physicians need to resolve. By focusing on active infection, the new biosensor aims to address that gap.

If the approach holds up in further development, it could offer value in both high-burden and resource-constrained settings. A selective test that works quickly may help clinicians isolate cases sooner, begin treatment earlier and reduce opportunities for onward transmission. That is especially important for a disease whose public health impact is shaped not only by mortality but by delays in diagnosis and interruption of care.

What the early results show

The reported trials indicate that the biosensor achieved a very low detection limit and strong selectivity against proteins from other respiratory pathogens, including influenza viruses, SARS-CoV-2, respiratory syncytial virus and other non-tuberculous mycobacteria. That matters because respiratory illnesses often overlap clinically, and false positives or poor discrimination can quickly reduce the practical value of a rapid test.

The source material presents the work as a promising step rather than a finished product. That is the right level of caution. Diagnostic advances frequently look compelling in early evaluations but still have to clear further technical, clinical and deployment hurdles before they reshape frontline care.

Even so, the concept addresses a real need. Tuberculosis control depends heavily on finding active cases quickly and reliably. A test that can do that in an hour, while differentiating active disease from other states of infection more effectively than some existing molecular approaches, would represent a meaningful advance.

The bigger significance is not simply speed. It is precision tied to action. In infectious disease control, the most useful diagnostic tools are the ones that change what clinicians do next. By targeting a marker of active tuberculosis, this biosensor is being positioned as exactly that kind of instrument.

This article is based on reporting by Medical Xpress. Read the original article.